Antitumor activity of the adduct between Carboplatin and (z-cyclodextrin has been tested against Sarcoma 180 ($18o) and Ehrlich ascites carcinoma (EAC) murine tumors. The preliminary toxicity has also been evaluated by histological examinations of the treated animals. The results show the adduct has less antitumor efficacy than and similar toxicity to Carboplatin.
Introduction
Carboplatin,diammine [1,1- [3] and that the inclusion markly increases aqueous stability of Carboplatin [4] . Whether the inclusion affects its antitumor activity remained an open question. In order to further evaluate the possibility of using clinically this adduct, we have studied the influence of inclusion on the antitumor activity and preliminary toxicity of Carboplatin, and report our results here.
Experimental part
The adduct of Carboplatin into o-cyclodextrin was synthesized and purified according to a reported method [4] . Its molecular formula was determined by elemental analysis and MS-FAB to be [(NH3)2Pt(C6H604 weights of drug and control groups were compared. Liver, spleen, kidney and lung of the mice were sumitted for histological examinations. Mice were transplanted ip with EAC cells, and 2 days later administrated iv with the drugs for 6 days. Within a 60 day experiment,the survival were recorded and activity of the drugs was assessed as the increase in life span. The tissues of the mice surviving for 28-30 days were also taken out for histological examinations.
Results and disscussion
The antitumor activity of the adduct and of Carboplatin in the corresponding two murine tumor models is listed in Table from which it can be seen that, although the adduct exhibits considerable antitumor efficacy, it is obvisiously less effective than Carboplatin at equivalent doses.
This means that the inclusion of o-cyclodextrin reduces antitumor activity of Carboplatin. No differences among the adduct and Carboplatin in pathological changes were observed, so the toxicity of the adduct is probably comparable to that of Carboplatin. The reason for the decrease in antitumor efficacy of the adduct is not yet understood but may be related to the difficulty in cellular uptake due to the larger size of the adduct and/or to the dissociation equilibrium between included and free Carboplatin, Carboplatin being only partly released from the adduct. The adduct shows no superiority over Carboplatin in activity and toxicity except its aqueous stability. Therefore there remains doubt of possible clinical uses of the adduct.
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